| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2971975 | The Journal of Heart and Lung Transplantation | 2009 | 6 Pages |
Abstract
Despite comparable 5-year survival with controls after heart transplantation, AsAMR rejection is associated with a greater risk of CAV. Trials to treat AsAMR to alter outcome are warranted.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Grace W. BS, Jon A. MD, Michael C. MD, Jignesh K. MD, PhD, Michelle M. MD, PhD, Elaine F. PhD, Krista K. BA, Abbas MD,